Achieved exceptional success in biopharmaceutical leadership, leveraging over 25 years of experience from lab bench to executive roles. Demonstrated expertise in talent development, fostering cross-functional team collaboration, and leading diverse professional environments. Proven track record in managing multi-national teams, overseeing third-party development projects in the U.S. and Europe, and navigating cross-company partnerships and international assignments in Germany and Puerto Rico. Articulate, personable, and results-driven leader in both large biopharma firms and start-ups.Realized consistent success in optimizing manufacturing processes and executing numerous technology transfers, scale-ups, and manufacturing campaigns for clinical and commercial stages, including process performance qualification (PPQ). Specialized in early and pivotal stage development for a diverse range of biologic modalities, such as autologous and allogenic cell therapies, guide RNA, mRNA and lipid nanoparticles (LNP), monoclonal antibodies, antibody-drug conjugates, Cas9, therapeutic proteins, and AAV vectors.Experienced in authoring and reviewing CMC sections of regulatory submissions (BLA/MAA, IND, and Briefing Book), and supporting pre-approval inspections (PAI) contributing to three commercial product approvals and three additional site licensure approvals. Notably, played a key role in the approval of the first CRISPR gene-edited therapeutic, CASGEVY™. Successfully drove new corporate sponsorship for SMDP Biotech, a non-profit career mentoring program that pairs diverse students with industry mentors. Committed to mentoring future leaders and helping all team members reach their full potential.